Bepridil hydrochloride
Cat. No.：YN360130
CAS No. ：68099-86-5
| 产品名称: | Bepridil hydrochloride |
| CAS No.: | 68099-86-5 |
| Chemical Name: | β-[(2-methylpropoxy)methyl]-N-phenyl-N-(phenylmethyl)-1-pyrrolidineethanamine, monohydrochloride |
| Synonyms: | CERM 1978 |
| 分子量: | 403.00 |
| 分子式: | C₂₄H₃₅ClN₂O |
| SMILES: | [H]Cl.CC(C)COCC(N1CCCC1)CN(C2=CC=CC=C2)CC3=CC=CC=C3 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Bepridil hydrochloride (CERM 1978) 是一种钙离子通道 (calcium channel) 抑制剂，具有抗心绞痛的作用。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Singh, B.N.The mechanism of action of calcium antagonists relative to their clinical applicationsBr. J. Clin. Pharmacol.21(Suppl 2),109S-121S(1986)
Perez-Reyes, E., Van Deusen, A.L., and Vitko, I.Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: Block by antihypertensives, antiarrhythmics, and their analogsJ. Pharmacol. Exp. Ther.328(2),621-627(2009)
Iijima, K., Chinushi, M., Izumi, D., et al.Effect of bepridil in atrial fibrillation inducibility facilitated by vagal nerve stimulation. Prevention of vagal nerve activation-induced shortening of the atrial action potential durationCirc. J.74(5),895-902(2010)
Sinha, N., and Sen, S.Predicting hERG activities of compounds from their 3D structures: Development and evaluation of a global descriptors based QSAR modelEur. J. Med. Chem.46(2),618-630(2011)
Sogaard, R., Ljungstrom, T., Pedersen, K.A., et al.KCNQ4 channels expressed in mammalian cells: Functional characteristics and pharmacologyAm. J. Physiol. Cell Physiol.280(4),C859-C866(2001)
Li, Y., Sato, T., and Arita, M.Bepridil blunts the shortening of action potential duration caused by metabolic inhibition via blockade of ATP-sensitive K+ channels and Na+-activated K+ channelsJ. Pharmacol. Exp. Ther.291(2),562-568(1999)
Sato, T., Costa, A.D.T., Saito, T., et al.Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotectionJ. Pharmacol. Exp. Ther.316(1),182-188(2006)
